Qiagen and Astellas Pharma to collaborate on companion diagnostics

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

QIAGEN N.V. and Astellas Pharma Inc. will collaborate to develop and commercialize companion diagnostics paired with Astellas drugs for use in cancer and other diseases.

Two initial projects in the collaboration focus on oncology and aim to pair Qiagen diagnostics with Astellas compounds in early-stage clinical trials: ASP5878, a fibroblast growth factor receptor inhibitor, and ASP8273, an EGFR inhibitor. Financial terms were not disclosed.

The scope of the agreement is not restricted to certain sample types, platforms, indications or biomarkers, giving Astellas access to Qiagen’s assays based on PCR, next generation sequencing and multi-modal testing technologies using liquid and tissue biopsies.

Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login